nccn guidelines for relapsed/refractory mcl
Published 4 years ago • 77 plays • Length 3:31Download video MP4
Download video MP3
Similar videos
-
4:43
how to manage relapsed/refractory mcl - new agents and unmet needs
-
1:56
how to treat patients with relapsed/refractory mantle cell lymphoma
-
2:58
case 1: nccn guidelines for treating myelofibrosis
-
3:06
r/r mcl: applying data into clinical practice
-
6:09
mcl and cll: nccn guidelines and treatment options
-
1:00:46
understanding the nccn clinical practice guidelines for histiocytic neoplasms
-
14:03
clinical considerations for therapy selection in relapsed/refractory mcl
-
8:24
the prevalence of mantle cell lymphoma - blood cancers video library
-
11:13
understanding mantle cell lymphoma
-
1:50:26
histiocytic neoplasms from behind the scope: a primer on diagnosing different subtypes
-
59:49
rebooting the btk inhibitor sequence in mcl
-
3:05
relapsed mantle cell lymphoma treatment landscape
-
1:01:34
what clinicians want to know about the management of relapsed/refractory mantle cell lymphoma
-
1:04:29
interprofessional perspectives on safety management with targeted therapy for b-cell malignancies
-
1:37
the 2024 update to the nccn guidelines for cll/sll: coming soon
-
1:19:12
the next phase of targeted therapy in mcl and dlbcl
-
1:00:46
understanding the nccn guidelines® for histiocytosis in adults webinar - june 2021
-
1:03:56
reviving the btk target & treatment sequencing in mcl
-
7:51
relapsed/refractory mantle cell lymphoma
-
1:20:06
update on relapsed/refractory mantle cell lymphoma | lrf webinars
-
2:31
unmet needs and future of r/r mantle cell lymphoma
-
5:36
achieving complete remission of mcl